Atlas Trials

A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC

Clinical trial NCT05205629 · UNKNOWN

Trial details

NCT number
NCT05205629
Sponsor
Shanghai Zhongshan Hospital
Status
UNKNOWN
Study type
OBSERVATIONAL
Hepatocellular CarcinomaDonafenib
Start date
2022-01-30
Primary completion
2024-01-30
Enrollment
150

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.